These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17287087)

  • 1. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
    Vink SR; van Blitterswijk WJ; Schellens JH; Verheij M
    Cancer Treat Rev; 2007 Apr; 33(2):191-202. PubMed ID: 17287087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
    Vink SR; Lagerwerf S; Mesman E; Schellens JH; Begg AC; van Blitterswijk WJ; Verheij M
    Clin Cancer Res; 2006 Mar; 12(5):1615-22. PubMed ID: 16533789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer mechanisms and clinical application of alkylphospholipids.
    van Blitterswijk WJ; Verheij M
    Biochim Biophys Acta; 2013 Mar; 1831(3):663-74. PubMed ID: 23137567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining anti-tumor alkyl-phospholipid analogs and radiotherapy: rationale and clinical outlook.
    Verheij M; Moolenaar WH; Blitterswijk WJ
    Anticancer Agents Med Chem; 2014 May; 14(4):618-28. PubMed ID: 24628238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis.
    Ruiter GA; Verheij M; Zerp SF; van Blitterswijk WJ
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):415-9. PubMed ID: 11173135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
    Vink SR; van der Luit AH; Klarenbeek JB; Verheij M; van Blitterswijk WJ
    Biochem Pharmacol; 2007 Nov; 74(10):1456-65. PubMed ID: 17803969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis.
    Santa-Rita RM; Henriques-Pons A; Barbosa HS; de Castro SL
    J Antimicrob Chemother; 2004 Oct; 54(4):704-10. PubMed ID: 15329361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
    van Blitterswijk WJ; Verheij M
    Curr Pharm Des; 2008; 14(21):2061-74. PubMed ID: 18691116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells.
    van der Luit AH; Vink SR; Klarenbeek JB; Perrissoud D; Solary E; Verheij M; van Blitterswijk WJ
    Mol Cancer Ther; 2007 Aug; 6(8):2337-45. PubMed ID: 17699729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets.
    Kvols LK
    J Nucl Med; 2005 Jan; 46 Suppl 1():187S-90S. PubMed ID: 15653668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.
    Jiménez-López JM; Ríos-Marco P; Marco C; Segovia JL; Carrasco MP
    Lipids Health Dis; 2010 Mar; 9():33. PubMed ID: 20338039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunological aspects of anticancer chemotherapy].
    Zitvogel L; Tesniere A; Apetoh L; Ghiringhelli F; Kroemer G
    Bull Acad Natl Med; 2008 Oct; 192(7):1469-87; discussion 1487-9. PubMed ID: 19445369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New concepts for phase I trials: evaluating new drugs combined with radiation therapy.
    Deutsch E; Soria JC; Armand JP
    Nat Clin Pract Oncol; 2005 Sep; 2(9):456-65. PubMed ID: 16264990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
    Zerp SF; Vink SR; Ruiter GA; Koolwijk P; Peters E; van der Luit AH; de Jong D; Budde M; Bartelink H; van Blitterswijk WJ; Verheij M
    Anticancer Drugs; 2008 Jan; 19(1):65-75. PubMed ID: 18043131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
    Baumann M; Krause M; Dikomey E; Dittmann K; Dörr W; Kasten-Pisula U; Rodemann HP
    Radiother Oncol; 2007 Jun; 83(3):238-48. PubMed ID: 17502118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition.
    Burgeiro A; Pereira CV; Carvalho FS; Pereira GC; Mollinedo F; Oliveira PJ
    Mitochondrion; 2013 Jan; 13(1):25-35. PubMed ID: 23164800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The concurrent chemoradiation paradigm--general principles.
    Seiwert TY; Salama JK; Vokes EE
    Nat Clin Pract Oncol; 2007 Feb; 4(2):86-100. PubMed ID: 17259930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.